Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
CAMBRIDGE, Mass., May 08, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 15, 2017, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2017.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 17355274. A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
